Michael Morin

Before joining Pfizer, Dr. Morin was an Assistant Professor in the Department of Pharmacology and Director of the Tumor Cell Biology Program at the Cancer Center, Northwestern University Medical School in Chicago. Mike Morin joined Pfizer in 1991, first working as a lab supervisor and soon thereafter as a manager. In his most recent role, Mike was Vice President of Drug Discovery in Pfizer Global R&D, and provided leadership to a group focusing on anti-bacterials, immunology and cancer in Pfizer's Groton Labs. Mike led the research teams that discovered and developed Tarceva, a drug approved for the treatment of lung and pancreatic cancer. Mike recently retired from Pfizer, and is now working as the President and CEO of Oncovia Therapeutics, Inc., a biotechnology company working to improve the treatment options for pediatric and adult cancer patients.